Outcome of patients separated according to a cutoff level of 10% day 16 blasts
| . | Patients with fewer than 10% day 16 blasts . | Patients with 10% or more day 16 blasts . | P . |
|---|---|---|---|
| Complete remission | 83.75% | 53.61% | < .0001 |
| Persistent leukemia | 2.83% | 32.53% | < .0001 |
| Overall survival | |||
| Median, mo | 27 | 11 | < .0001 |
| 5-y survival | 35.4% | 13.7% | |
| Event-free survival | |||
| Median, mo | 14 | 3 | < .0001 |
| 5-y EFS | 27.4% | 10.9% | |
| Overall survival in patients with CR | |||
| Median, mo | 37 | 18 | .01972 |
| 5-y survival | 40.6% | 25.4% | |
| Relapse-free survival in patients with CR | |||
| Median, mo | 19 | 10 | .01035 |
| 5-y RFS | 32.9% | 20.8% | |
| Freedom from relapse in patients with CR | |||
| Median, mo | 21 | 10 | .01523 |
| 5-y FR | 37.1% | 27.4% |
| . | Patients with fewer than 10% day 16 blasts . | Patients with 10% or more day 16 blasts . | P . |
|---|---|---|---|
| Complete remission | 83.75% | 53.61% | < .0001 |
| Persistent leukemia | 2.83% | 32.53% | < .0001 |
| Overall survival | |||
| Median, mo | 27 | 11 | < .0001 |
| 5-y survival | 35.4% | 13.7% | |
| Event-free survival | |||
| Median, mo | 14 | 3 | < .0001 |
| 5-y EFS | 27.4% | 10.9% | |
| Overall survival in patients with CR | |||
| Median, mo | 37 | 18 | .01972 |
| 5-y survival | 40.6% | 25.4% | |
| Relapse-free survival in patients with CR | |||
| Median, mo | 19 | 10 | .01035 |
| 5-y RFS | 32.9% | 20.8% | |
| Freedom from relapse in patients with CR | |||
| Median, mo | 21 | 10 | .01523 |
| 5-y FR | 37.1% | 27.4% |